Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 05, 2027 · 160 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or framework maximum provided. Revenue depends entirely on actual prescriptions and discounts agreed.

Open-house agreements automatically terminate if a competitive discount agreement for the same substance takes effect (...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Supply of pharmaceutical products containing Golimumab (ATC L04AB06)
  • Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Afficher le résumé complet

Open-house model for non-exclusive discount agreements (Rabattverträge) on Golimumab (ATC L04AB06) with AOK Bayern. All interested pharmaceutical companies meeting eligibility can conclude identical, non-negotiable contracts. No competitive selection; contracts can be entered at any time until 05.02.2027, subject to rolling submission deadlines. Estimated value not provided. Contract duration 01.04.2025 to 31.03.2027. The procedure is not subject to public procurement law; it is a voluntary open-house model.

Risques

No estimated value or framework maximum provided. Revenue depends entirely on actual prescriptions and discounts agreed.

Open-house agreements automatically terminate if a competitive discount agreement for the same substance takes effect (...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible

Administrative

  • Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Contract must be submitted in duplicate (paper) or with qualified electronic signature

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06

Non-exclusive discount agreements for the active substance Golimumab (ATC L04AB06) for pharmaceutical companies. Contracts start monthly if documents are complete by the 5th of the month. Deadline for contract conclusion: 05.02.2027. Contract duration: 01.04.2025 to 31.03.2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2025 - Mar 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 05, 2027

Détails de la procédure

Date de publication
17 Feb 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
106852-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30